174 related articles for article (PubMed ID: 37982279)
1. Pediatric acute myeloid leukemia - novel approaches.
Karol SE; Gueguen G
Curr Opin Hematol; 2024 Mar; 31(2):47-52. PubMed ID: 37982279
[TBL] [Abstract][Full Text] [Related]
2. The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies.
Pommert L; Tarlock K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):603-610. PubMed ID: 36485125
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
4. Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
McCurdy SR; Luger SM
Haematologica; 2021 Oct; 106(10):2544-2554. PubMed ID: 34320781
[TBL] [Abstract][Full Text] [Related]
5. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
6. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
Bazinet A; Assouline S
Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
[No Abstract] [Full Text] [Related]
7. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
8. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults.
Goldenson BH; Goodman AM; Ball ED
Expert Opin Biol Ther; 2021 Jul; 21(7):849-862. PubMed ID: 32990476
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic strategies for high-risk acute myeloid leukemia.
Menghrajani K; Tallman MS
Curr Opin Hematol; 2018 Mar; 25(2):90-94. PubMed ID: 29283906
[TBL] [Abstract][Full Text] [Related]
11. Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.
Cooper TM; Alonzo TA; Tasian SK; Kutny MA; Hitzler J; Pollard JA; Aplenc R; Meshinchi S; Kolb EA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30584. PubMed ID: 37480164
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
14. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
15. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
16. Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.
Chen KTJ; Gilabert-Oriol R; Bally MB; Leung AWY
Pharm Res; 2019 Jun; 36(9):125. PubMed ID: 31236772
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Immunol; 2021; 12():683595. PubMed ID: 34484181
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab Ozogamicin Monotherapy Is a Well-tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature.
Blain S; Payette N; Bittencourt H; Johnston DL
J Pediatr Hematol Oncol; 2023 Nov; 45(8):436-444. PubMed ID: 37807192
[TBL] [Abstract][Full Text] [Related]
19. New Treatment Options for Acute Myeloid Leukemia in 2019.
Cerrano M; Itzykson R
Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
[TBL] [Abstract][Full Text] [Related]
20. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Tang K; Schuh AC; Yee KW
Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]